BROOKS vs SMSPHARMA: Stock Comparison

Brooks Laboratories Limited vs SMS Pharmaceuticals Limited

Live data: 16 April 2026, 4:01 PM IST • Source: NSE and company filings

SMS Pharmaceuticals Limited is the larger company by market capitalisation. Brooks Laboratories Limited shows a lower P/E, a higher ROE and lower leverage, while SMS Pharmaceuticals Limited shows a higher dividend yield, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Brooks Laboratories Limited and SMS Pharmaceuticals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BROOKS is more favourable on 7 of 13 scored metrics and SMSPHARMA on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SMSPHARMA is the larger company
₹3,560 Cr vs ₹185 Cr
P/E Ratio
BROOKS has a lower P/E
8.22x vs 34.95x
P/B Ratio
BROOKS has a lower P/B
1.65x vs 4.54x
EPS
SMSPHARMA has higher earnings per share
₹11.17 vs ₹7.32
Dividend Yield
SMSPHARMA has a higher dividend yield
0.1% vs 0%
Revenue Growth (TTM YoY)
SMSPHARMA has faster revenue growth
-4.1% vs -6.37%
EPS Growth (TTM YoY)
SMSPHARMA has faster EPS growth
49.2% vs 0%
Qtr Sales Growth
BROOKS has stronger quarterly sales growth
42.3% vs -4.13%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBROOKSSMSPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBROOKSSMSPHARMA
Live Price₹69.58₹380.75
Day Change-3.45%-2.85%
Volume91,9991.03 L
52-Week High₹163.9₹447.8
52-Week Low₹36.3₹207.99
Distance from 52W High-57.55%-14.97%

Valuation

MetricBROOKSSMSPHARMA
Market Cap₹185 Cr₹3,560 Cr
P/E Ratio8.22x34.95x
P/B Ratio1.65x4.54x
EPS₹7.32₹11.17
Book Value₹33.3₹81.83
Dividend Yield0%0.1%

Growth

MetricBROOKSSMSPHARMA
Revenue Growth (TTM YoY)-6.37%-4.1%
EPS Growth (TTM YoY)0%49.2%
Qtr Sales Growth42.3%-4.13%
Qtr Profit Growth498%61%

Profitability & Leverage

MetricBROOKSSMSPHARMA
ROE20.04%14.3%
ROCE-9.93%13.3%
Net Margin28.67%11.5%
Operating Margin7.74%19.3%
Debt to Equity0.06x0.46x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBROOKSSMSPHARMA
Promoter Holding52.62%68.07%
FII Holding0% 0.17 pp0.65% 0.34 pp
DII Holding10.38%2.83% 0.19 pp
Public Holding37% 0.16 pp28.45% 0.15 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Brooks Laboratories Limited and SMS Pharmaceuticals Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.